Glenmark’s favipiravir trial shows 40% faster COVID-19 recovery
Category: #health  By Saipriya Iyer  Date: 2020-07-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Glenmark’s favipiravir trial shows 40% faster COVID-19 recovery

Glenmark Pharmaceuticals has recently announced the positive result from its Phase 3 clinical trial of favipiravir, a sought-after drug, which was conducted among the COVID-19 patients. The study has shown the effectiveness of the drug, enabling a faster recovery of the patients.

The Mumbai-based pharmaceutical company had conducted the favipiravir trial on 150 COVID-19 patients who showed mild to moderate symptoms across 7 clinical sites in India. The study was conducted to examine the safety and efficacy of this Japanese drug that is used for the treatment of flu. Out of these 150 subjects, 90 patients had mild symptoms while the remaining patients had moderate symptoms.

Favipiravir is being examined in various ongoing COVID-19 clinical trials across the globe. The drug selectively inhibits RdRp (RNA-dependent RNA polymerase) and the viral replication phase of the SARS-CoV-2.

As per the statement made by Glenmark, there has been a 40% faster achievement of the clinical cure among the patients, which is considered as the assessment of normalization of the clinical signs by physicians. These clinical signs include cough, respiratory rate, oxygen saturation, and temperature.

The company’s statement further claimed that a statistically significant median time reduction to the clinical cure had been observed in the favipiravir arm in 3 days, as compared to the control arm. In the control arm, the patients were treated without the drug and kept under the standard supportive care for 5 days. This standard supportive care was provided in accordance with the norms of the ICMR (Indian Council of Medical Research).

In April, Glenmark had gained approval from the DCGI (Drug Controller General of India) to commence the clinical trials of the recent antiviral medicine. The data or findings from the trials have not been reviewed independently and shared with the public. The company is planning to submit the data from the recent Phase 3 clinical trial for publication in a peer-reviewed journal in the next few weeks.

Source credit:

https://theprint.in/health/covid-patients-given-favipiravir-showed-40-faster-recovery-glenmark-trial-results-claim/466327/



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
By Saipriya Iyer

Boehringer Ingelheim, a pharmaceutical company, has recently announced the enrollment of 1st patient in its Phase 3 InPedILD™ trial. The trial will evaluate the dose and safety profile of nintedanib among childre...

Medtronic to turn Hyderabad into R&D hub with $160.3M investment
Medtronic to turn Hyderabad into R&D hub with $160.3M investment
By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company s...

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
By Saipriya Iyer

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s terminat...